Who Should Get Low-Dose CT Lung Cancer Screening — and What Happens When a Nodule Is Found

Research-informed explainer — last updated April 12, 2026

Low-dose CT (LDCT) lung cancer screening reduces lung cancer mortality by approximately 20% in high-risk current and former smokers and is covered by Medicare and most private insurance for eligible patients — yet fewer than 10% of people who qualify for screening actually receive it. The test takes about 10 minutes, requires no contrast dye or injections, and exposes patients to a fraction of the radiation of a standard CT scan.

The science behind lung cancer screening and nodule management comes from radiologists and oncologists who have shaped the field. Ella Kazerooni, Terry M. Silver M.D. Legacy Professor of Radiology at the University of Michigan, helped develop the Lung Image Database Consortium (LIDC), the standardized reference database of lung nodules used to train radiologists and AI algorithms (2,697 citations), and published the Lung-RADS performance analysis in the National Lung Screening Trial (488 citations) — she is one of the architects of the reporting system that governs how radiologists describe screening findings. Jonathan Goldin, Professor of Radiology at UCLA, contributed to the National Lung Screening Trial overview published in Radiology (1,256 citations) — the design paper for the pivotal trial that established the 20% mortality reduction. Florian Fintelmann, Associate Professor of Radiology at Harvard and Director of Thoracic Percutaneous Ablation at Massachusetts General Hospital, published a comprehensive 2022 Lancet review on lung cancer screening (380 citations) and a study on barriers to screening engagement from both patient and provider perspectives (194 citations). Julie Brahmer at Johns Hopkins and Bruce Johnson at Dana-Farber provide context on the treatment available when screening detects lung cancer — including pembrolizumab and BRAF-targeted therapy — demonstrating that early detection now leads to more personalized and potentially curative treatment options.

Who qualifies for LDCT lung cancer screening?

The United States Preventive Services Task Force (USPSTF) 2021 criteria for annual LDCT screening are:

• Age 50–80 years
• 20 pack-year smoking history (one pack per day for 20 years, or two packs per day for 10 years, etc.)
• Currently smoke, or quit within the past 15 years

Annual screening continues until age 80, or until the patient has not smoked for more than 15 years, or until a health problem makes curative-intent lung cancer treatment impossible or unattractive.

Insurance coverage: The Affordable Care Act requires most private insurance plans to cover LDCT screening without cost-sharing (no copay) for eligible patients. Medicare covers annual LDCT lung cancer screening (G-code G0297 or equivalent) with the same eligibility criteria.

A shared decision-making discussion with your primary care provider is required before the first screening exam, covering the benefits, limitations, and potential harms (including false positives and unnecessary procedures).

Why participation rates are so low — and why that matters

Florian Fintelmann's barriers research found that both patients and providers underestimate screening eligibility, face logistical obstacles (no referral order received, no nearby accredited center), and hold beliefs that a past smoking history is too embarrassing to discuss or that abnormal findings will lead to unnecessary procedures. Patient-level barriers included fear of finding cancer and a fatalistic belief that nothing could be done anyway.

In reality, when lung cancer is detected by screening, it is far more likely to be at an early, operable stage. Among NLST participants whose cancers were screen-detected, a much higher proportion were stage I or II compared with the general lung cancer population. Five-year survival for stage I non-small cell lung cancer exceeds 60–80% depending on subtype — versus approximately 6% for stage IV disease.

What happens after a screening CT: understanding Lung-RADS

The Lung-RADS (Lung CT Screening Reporting and Data System), developed by the American College of Radiology with Ella Kazerooni as a principal contributor, standardizes how radiologists categorize screening CT findings.

Lung-RADS 1 and 2 account for about 92% of screening CT results. A Lung-RADS 3 result does not mean cancer — it means the radiologist found a nodule that is likely benign but worth watching at 6 months. A Lung-RADS 4A or 4B result warrants further evaluation, which may involve a follow-up CT, a PET scan, or bronchoscopy or CT-guided biopsy to obtain tissue.

The Kazerooni Lung-RADS performance analysis in the NLST showed that Lung-RADS reduced the false positive rate substantially compared with the NLST's own reporting criteria, while maintaining high sensitivity for cancer detection.

What finding a nodule does not mean

A lung nodule found on screening CT is not necessarily cancer. More than 95% of lung nodules detected on screening CTs are benign — caused by healed infections (histoplasmosis, tuberculosis), scarring, lymph nodes, or vascular structures. The Lung-RADS category reflects the radiologist's estimate of malignancy risk based on nodule size, density (solid vs. subsolid vs. ground-glass), shape, location, and growth rate. Most nodules found on screening require only surveillance with repeat imaging, not biopsy or surgery.

What happens if cancer is found

Early-stage lung cancer detected by LDCT screening is now treated with a broader array of options than previously available. Surgery — either lobectomy or, for small peripheral tumors, sublobar resection — remains the standard for operable patients. For patients who cannot undergo surgery, stereotactic body radiotherapy (SBRT) achieves excellent local control. Molecular profiling (EGFR, ALK, BRAF, KRAS) and PD-L1 testing are now performed on resected specimens to guide adjuvant therapy decisions — including adjuvant osimertinib for EGFR-mutant tumors and adjuvant pembrolizumab for stage IB–III disease with appropriate PD-L1 status.

Talking to your doctor: bridging the gap between eligibility and screening

Fintelmann's barrier research showed that many primary care providers do not routinely ask about smoking history in sufficient detail to identify eligible patients, and many patients have not heard of lung cancer screening. If you have a smoking history of 20 or more pack-years and are currently between ages 50 and 80, you can ask directly: "Am I eligible for low-dose CT lung cancer screening?"

If your doctor does not have an established referral pathway, major cancer centers and most radiology departments at academic medical centers have dedicated lung cancer screening programs with radiologists trained to read screening CTs and Lung-RADS reporting.

Questions to ask your doctor

• Do I qualify for annual low-dose CT lung cancer screening based on my age and smoking history?
• Is my insurance covering this test, and which accredited screening center would you recommend?
• If a nodule is found, who will explain the Lung-RADS category to me and what follow-up will be needed?
• If lung cancer is detected, does this center have the capacity to perform molecular testing and offer all available treatment modalities, including SBRT and molecular targeted therapy?
• What can I do to reduce my lung cancer risk further, including smoking cessation support?

The bottom line

Low-dose CT lung cancer screening is the only cancer screening test proven to reduce mortality from one of the most lethal cancers. It is underused — largely because of poor awareness among both patients and providers — despite straightforward eligibility criteria and broad insurance coverage. If you are between 50 and 80 years old with a 20-pack-year smoking history and currently smoke or quit within the past 15 years, you are eligible. The test takes minutes, and when it catches cancer early, the treatment options are substantially better and the outcomes dramatically improved.